The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
30
1,000 μg retinyl palmitate twice a day for 6 months
500 mg NAM twice a day for 6 months
Identical placebo pills twice a day
Rhode Island Hospital
Providence, Rhode Island, United States
RECRUITINGChange of Blood Vitamin A and Nicotinamide Levels
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.